Myasthenia Gravis Treatment Market 2024-2033: Analysis, Trends & Competitive Landscape

The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.42 billion in 2023 to $1.54 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to cholinesterase inhibitors, thymectomy procedures, immunosuppressive therapies, emergence of plasma exchange, patient advocacy.

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.05 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to biologics and monoclonal antibodies, genetic and precision medicine, emerging immune modulators, neuroprotective strategies, biosimilar medications. Major trends in the forecast period include digital therapeutics, collaborative research initiatives, patient-centric approaches, real-world evidence utilization, long-term safety monitoring.

Market Overview -
Myasthenia gravis treatment refers to the process of providing health care services by health care providers and taking care of a patient to combat myasthenia gravis, an autoimmune neuromuscular disease-causing fatigue and weakness in the skeletal muscles.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp

Myasthenia Gravis Treatment Market Surges In Response To Escalating Disease Prevalence
The surge in the prevalence of myasthenia gravis is expected to propel the growth of the myasthenia gravis treatment market going forward. Myasthenia gravis refers to an autoimmune neuromuscular disease condition in which patients experience fatigue and weakness in the skeletal muscles. Myasthenia gravis treatment is the process of providing health care services and taking care of a patient to combat myasthenia gravis. Thus, the surge in the prevalence of myasthenia gravis is boosting sales in the myasthenia gravis treatment market. For instance, in January 2022, according to the data published by the National Organization for Rare Disorders, a US-based non-profit organization providing support for individuals with rare diseases, autoimmune myasthenia gravis had an estimated prevalence of 14-40 per 100,000 individuals in the United States. For instance, in December 2021, according to the study conducted by the Iran-based Kermanshah University of Medical Sciences and University Putra Malaysia, the global prevalence of myasthenia gravis was estimated to be 12.4 people per 100,000 people. Therefore, the surge in the prevalence of myasthenia gravis is driving the growth of the myasthenia gravis treatment market.

Competitive Landscape -
Major companies operating in the myasthenia gravis treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Avadel Pharmaceuticals plc, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., Zenyaku Kogyo Co. Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

Argenx's Vyvgart Breakthrough Marks A New Era In Myasthenia Gravis Treatment With FDA Approval
Product innovations are a key trend gaining popularity in the myasthenia gravis treatment market. Major companies operating in the myasthenia gravis treatment market are focused on developing new solutions to sustain their position in the market. For example, in December 2021, Argenx SE, a Netherlands-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its innovative drug VYVGARTô (efgartigimod alfa-fcab) for the treatment of anti-acetylcholine receptor (AChR) antibody-positive adult patients with generalized myasthenia gravis. With this approval, VYVGART has become the first and only FDA-approved neonatal Fc receptor (FcRn) blocker used for generalized myasthenia gravis treatment. The company has reached agreements in principle with several regional and national commercial payers to structure a value-based agreement, providing appropriate access for patients and predictability of cost for payers.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report

Key Segments -
The myasthenia gravis treatment market covered in this report is segmented -
1) By Treatment: Medication, Surgery, Other Treatments
2) By Medication Type: Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, Other Medication Types
3) By End-Use: Hospitals, Clinics, Other End-Uses

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.